Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Apr 18, 2019 • 9:00 AM EDT
Ligand to Report First Quarter 2019 Results on May 2nd
Mar 21, 2019 • 9:00 AM EDT
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Mar 12, 2019 • 4:01 PM EDT
Ligand to Participate in Four Upcoming Investor Conferences
Apr 9, 2019
See all events
Mar 18, 2019 • 4:30pm EDT
Laguna Niguel, California
Mar 13, 2019 • 9:00am EDT
May 2, 2019 • 4:30pm EDT
May 29, 2019
Jun 6, 2019 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
CStone Pharmaceuticals announces first patient dosed in Phase 3 study for OmniAb-derived CS1001 in combo with chemo… https://t.co/NtEZgsgB3m
$APVO provides update on OmniAb-derived APVO436; Phase 1 data anticipated in Q4'19 https://t.co/vi8VLXmAnF
Viking Therapeutics presents new data from Phase 2 of VK2809 in patients with Non-Alcoholic Fatty Liver Disease (NA… https://t.co/mcXrxZpoMR